| Age | Gender | Weight | Height | Aethiology | Lesion level | Time since lesion (months) | OF-OE | OF-CE | CF-OE | CF-CE |
---|---|---|---|---|---|---|---|---|---|---|---|
PT1* | 19 | M | 62 | 173 | T | T7 | 6 | Y | Y | N | N |
PT2* | 34 | F | 68 | 175 | NT (Inflammatory) | C5 | 24 | Y | Y | Y | Y |
PT3* | 66 | M | 74 | 167 | NT (Degenerative) | T11 | 15 | Y | Y | Y | Y |
PT4 | 37 | M | 64 | 171 | T | C6 | 13 | Y | Y | Y | Y |
PT5* | 52 | M | 68 | 169 | NT (Vascular) | T12 | 10 | Y | Y | Y | Y |
PT6* | 33 | F | 55 | 167 | T | T11 | 8 | Y | Y | N | N |
PT7* | 34 | F | 60 | 176 | NT (Vascular) | T8 | 6 | Y | Y | Y | Y |
PT8* | 54 | F | 70 | 168 | NT (Degenerative) | L5 | 32 | Y | Y | Y | N |
PT9* | 35 | F | 66 | 172 | NT (Degenerative) | L4 | 8 | Y | N | Y | N |
PT10 | 41 | M | 88 | 177 | T | L3 | 5 | Y | Y | N | N |
PT11* | 64 | M | 78 | 160 | NT (Inflammatory) | T5 | 13 | Y | Y | N | N |
PT12 | 84 | M | 53 | 165 | NT (Inflammatory) | L1 | 8 | Y | Y | N | N |
PT13 | 52 | M | 80 | 173 | NT (Degenerative) | C7 | 8 | Y | Y | Y | Y |
PT14* | 30 | M | 65 | 173 | T | L3 | 9 | Y | Y | Y | Y |
PT15 | 40 | M | 73 | 178 | T | L3 | 6 | Y | Y | Y | Y |
PT16* | 29 | M | 65 | 181 | T | T10 | 8 | Y | N | N | N |
PT17* | 61 | F | 80 | 159 | NT (Inflammatory) | T7 | 14 | Y | N | N | N |
PT18* | 33 | F | 85 | 182 | T | C6 | 8 | Y | Y | Y | Y |
PT19* | 59 | F | 60 | 158 | NT (Degenerative) | C5 | 72 | Y | Y | Y | Y |
PT20* | 69 | M | 75 | 165 | T | C5 | 13 | Y | Y | Y | Y |
PT21* | 44 | F | 57 | 178 | NT (Degenerative) | D1 | 75 | Y | Y | Y | Y |
PT22* | 51 | M | 74 | 173 | NT | C7 | 9 | Y | Y | Y | Y |
PT23 | 60 | M | 65 | 170 | NT (Degenerative) | C7 | 8 | Y | Y | Y | Y |
Medium (s.d.) | 48,27 (15,94) | 14Â M - 9Â F | 69,22 (9,37) | 163,45 (32,65) | 60.9% NT 39.1%Â T | Â | 16.43 (19,03) | Â | Â | Â | Â |